Table 3

Summary of previous studies examining the prevalence of AFD in patients with HCM

Authors	Year	Screened population	Screening method	Prevalence
Nakao et al6	1995	230 Male patients with echocardiographic evidence of LVH (septum or left ventricular posterior wall thickness ≥13 mm) from a cohort of 1603 male subjects	Plasma α-galactosidase A activity	3.0%
Sachdev et al7	2002	79 Consecutive men with HCM (unexplained LVH with a MLVWT ≥13 mm) first diagnosed ≥40 years of age and 74 HCM men first diagnosed <40 years of age	Plasma α-galactosidase A activity	6.3% in patients diagnosed ≥40 years 1.4% in patients diagnosed <40 years
Ommen et al12	2003	100 Consecutive HCM patients (44 men) who underwent septal myectomy	Transmission electron microscopy of myectomy tissue	0.0%
Chimenti et al8	2004	34 Consecutive female patients with HCM (unexplained LVH with a MLVWT ≥13 mm)	Biventricular endomyocardial biopsy and leucocyte α-galactosidase A activity	11.8%
Arad et al9	2005	75 Consecutive patients with HCM (30 women, 45 men) (unexplained LVH with a MLVWT ≥13 mm)	Genetic analysis	0.0%
Morita H et al10	2006	50 Patients (18% women) with echocardiographic evidence of unexplained LVH (MLVWT >13 mm) from a cohort of 1862 subjects	Genetic analysis	2.0%
Monserrat et al11	2007	508 Consecutive patients (328 men, 180 women) with HCM diagnosed according to the WHO/ESC criteria	Plasma α-galactosidase A activity	1.0%
Hagege AA et al22	2011	392 patient with HCM (unexplained LVH with a MLVWT ≥ 15 mm) (278 men) aged 18–79 years	α-galactosidase A assay on dried blood spot using a filter paper test	1.0%

AFD, Anderson–Fabry Disease; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; MLVWT, maximal left ventricular wall thickness.